Our vision is to develop breakthrough therapies that have the potential to prevent and reverse Type 2 Diabetes
Despite advances in treatment and decades of investment, T2D and its related metabolic diseases continue to be a principal driver of morbidity and mortality in the 21st century. In the United States alone, approximately 30 million people are diagnosed with T2D, and approximately half of these individuals are not able to achieve targeted disease control.
At Fractyl Health, we are singularly focused on developing therapies that are designed to target root causes of T2D and delivering those therapies to patients as broadly and rapidly as possible.Learn more about T2D
Revita® is an endoscopic procedural therapy that is enabled by our proprietary device system. Revita is designed to remodel the lining of the duodenum via hydrothermal ablation in order to edit abnormal nutrient sensing and signaling mechanisms that we believe are a root cause of T2D.Learn About Revita®
IN DEVELOPMENT: REJUVA®
Rejuva® is a novel pancreatic gene therapy platform currently in preclinical development. The Rejuva platform is designed to potentially enable long-term remission of T2D by restoring insulin production and islet function in patients with advanced T2D.Learn about Rejuva®